Innocoll's CollaRx gentamicin implant approved in Canada
Vancouver, Canada-based Innocoll Pharmaceuticals has received a class IV medical device licence for its CollaRx Gentamicin surgical implant from the domestic regulator, Health Canada.
The device is a biodegradable leave-behind surgical implant impregnated with the broad-spectrum aminoglycoside antibiotic gentamicin. The product was developed using Innocoll's proprietary collagen-based technology, CollaRx, and has been approved in 49 countries as either a medicinal product for the treatment and prevention of surgical site infections or as a medical device. It is currently in Phase III clinical development in the USA for the prevention of surgical site infections.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze